GEN Podcasts

The Future of Bioinformatics: Scaling Interactive and Computational Workflows with Seqera

Fri, 11 Apr 2025 20:17:04 GMT

Smart Vector Design for Improved Cell and Gene Therapies

Tue, 08 Apr 2025 15:10:24 GMT

In the episode, we’re talking about vector design and delivery for gene therapies. The field of cell and gene therapies is advancing, but there are still challenges with delivery vectors that need to be addressed. In this podcast, experts discuss current immunogenicity hurdles, evolving DMPK strategies, and a new generation of bioanalytical tools that are contributing to the progress in the field.

Hosted on Acast. See acast.com/privacy for more information.

From Functional Genomics to Cell Therapy: The Role of CRISPR-based Gene Editing

Tue, 08 Apr 2025 15:05:14 GMT

There are an estimated 6,000 Mendelian diseases, most of which still lack cures. Gene editing is an essential technology for studies aimed at generating data about disease-causing gene mutations and networks in order to identify optimal therapeutic targets. In this episode, experts will discuss applications of gene editing to improve scientists understanding of the relationship between variant and disease in functional genomics studies. They will also talk about the Dharmacon product suite which is designed for CRISPR-based targeted editing in a wide range of cells.

Hosted on Acast. See acast.com/privacy for more information.

Precision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene Therapies

Fri, 28 Mar 2025 17:47:45 GMT

In this episode, you’ll hear a group of experts discussing base editing and how the technology is helping scientists engineer powerful cell therapies for various diseases including novel CAR-T therapies and hypoimmunogenic induced pluripotent stem cells. During the discussion, they will cover the merits of the Pin-point base editing platform, which introduces gene modifications without relying on double-strand DNA breaks, as well as how TotalSeq reagents, which confirm the safety and efficiency of editing with the Pin-point platform, support single cell multiomics analysis of edited cells.

Hosted on Acast. See acast.com/privacy for more information.

Cas-CLOVER: An advanced gene editing technology capable of meeting crop improvement challenges

Mon, 22 Jan 2024 17:34:18 GMT

This GENcast is the final installment in a 3-part series on Cas-CLOVER, “the proven alternative to CRISPR/Cas9,” sponsored by Demeetra AgBio. Demeetra has built extensive gene editing know-how, complementing its internally developed as well as globally sourced portfolio of intellectual property, which it transfers to its partners through simple commercial licenses with freedom to operate.

Jack Crawford, CEO of Demeetra, sat down with Dr. Leena Tripathi, Director of the Eastern Africa Hub and Leader of the Biotechnology Program at the International Institute of Tropical Agriculture (IITA), and David Norman, Senior Scientist in the Plant Systems Group at Demeetra.

They discuss how combining advanced gene editing techniques with traditional methods for plant breeding can meet the global challenges of feeding a rapidly growing population. Additionally, they discuss their brief communication in Plant Biotechnology Journal that was published in 2023 demonstrating Cas-CLOVER as an alternative genome-editing tool to CRISPR/Cas9 by targeting MusaPDS in the banana genome.

Hosted on Acast. See acast.com/privacy for more information.

The Possibilities of Cas-CLOVER and piggyBac

Thu, 14 Dec 2023 15:15:30 GMT

This GENcast is part 2 of a 3-part series on Cas-CLOVER, “the proven alternative to CRISPR/Cas9,” sponsored by Demeetra AgBio. Demeetra has built extensive gene editing know-how, complementing its internally developed as well as globally sourced portfolio of intellectual property, which it transfers to its partners through simple commercial licenses with freedom to operate.

Jack Crawford, CEO of Demeetra, sat down with Dr. Molly Duman Scheel, professor in the department of medical and molecular genetics at the Indiana University School of Medicine - South Bend, and Dr. Corey Brizzee, director of gene editing at Demeetra.

The discussion focuses on the use of advanced gene editing technologies to create scalable, and eco-friendly biopesticides as described in the panelists’ latest publications in Journal of Fungi’s special issue “Development and Utilization of Yeast Resources” and Fermentation’s special issue “Advances in Yeast Biotechnology from Genomics to Industry.”

Panelists

“Two of the primary obstacles to using RNAi pesticides is the steep cost of production. How are you going to get it into the field, and how is it going to be stable, [gene edited] yeast solve both of these issues for us”—Dr. Molly Duman Scheel

“We wanted to make the expression as high as we could…we created a biomanufacturing platform [in yeast] with Cas-CLOVER by editing nutritional markers…this allowed for easy selection when we combined [the platform] with piggyBac to deliver the biopesticide RNAi”—Dr. Corey Brizzee

Hosted on Acast. See acast.com/privacy for more information.

Addressing Barriers in Gene Therapy

Thu, 14 Dec 2023 15:00:16 GMT

In this podcast episode, join us as we delve into addressing regulatory challenges in gene therapy with María Orío, the Head of Regulatory Affairs at Viralgen. Learn about the mission of Viralgen as a Contract Development and Manufacturing Organization specializing in Adeno-Associated Virus (AAV) gene therapy products. Uncover the unique challenges faced by the gene therapy industry, from the evolving regulatory landscape to the setting of acceptance criteria with limited available data. Learn how Viralgen addresses these challenges, leveraging historical data and innovative approaches. Gain valuable insights from the Chemistry, Manufacturing, and Controls (CMC) perspective, while learning how regulatory agencies are actively supporting sponsors in their quest for life-changing treatments.

Hosted on Acast. See acast.com/privacy for more information.